ClinicalTrials.gg
Not yet recruitingNCT06270355SMARTUpdated Feb 28, 2024

Stockholm Mammography Risk Stratified Trial

A Phase 3 interventional study of Risk based screening in Breast Cancer, sponsored by Karolinska Institutet. Not yet recruiting. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Karolinska Institutet · Phase 3, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70,000
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.

Planned enrollment
Largest of 18
70,000 · median 175
Started
2024
the only one that year
Phase 3
3 of 19
2 open now
Registered
16th of 19
by date

Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one has the largest planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Karolinska Institutet, or all of them as a file.
02

Study summary

SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months.

Read the detailed description

Aims: The overarching aim of SMART is to compare the effectiveness of current screening practice with individualised breast cancer screening. In SMART women who recently had a normal mammogram will be randomised to either age based or individualised screening. Women randomised to individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an artificial intelligence (AI) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months. The possible benefits of individualised screening will be contrasted to the possible harms defined as unnecessary recalls, biopsies and induced anxiety and worry.

Primary Objectives: The primary benefit endpoint is a comparison of the proportion of interval cancers in the intervention and comparison group. The primary safety endpoint is the number of screen-initiated recalls and biopsies which do not lead to a cancer diagnosis.

Secondary Objectives: The secondary benefit endpoint is a comparison of the tumor characteristics of diagnosed cancers in the intervention and comparison group. The investigators will also compare differences in cancer worry, anxiety and / or depression between the intervention and control groups.

Explorative Objectives: To describe the possible side effects related to contrast enhanced mammography and compare them to those experienced after an ordinary mammogram. Cost-effectiveness as measured using incremental cost-effectiveness ratio and willingness-to-pay amount.

Primary Endpoint: For women at high 2-year risk in the intervention arm interval cancers are defined as cancers diagnosed in the interval between contrast enhanced mammography (CEM) and 12-month mammogram plus in the interval between 12- and 24-month interval. For the remaining women in the trial interval cancers are defined as cancers diagnosed between baseline mammography and 24-month mammography.

Information on date of diagnosis and mode of detection (screen detected or interval cancer) is derived from the National Quality Registry for Breast Cancer. To certify the correct diagnosis, the investigators will also use the electronic medical records, Take Care, at Södersjukhuset. Information on number of recalled women and number of biopsies will gathered from the Radiation Information System at the hospital.

Secondary Endpoint: Information on date of diagnosis and tumour characteristics (eg. stage, receptor status) is derived from the National Quality Registry for Breast Cancer. The investigators will compare how the screening modalities are perceived using answers from the self-reported Cancer Worry Scale and State Trait Anxiety Inventory.

Explorative Endpoint: The possible side effects related to contrast enhanced mammography and ordinary mammography will be identified using the self-reported Test Morbidity Index.

Study design: SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months.

Study population: Women invited for screening according to the Swedish National Breast Cancer Screening Program at Södersjukhuset, that is, age range 40 - 74 years of age, will be invited to participate in SMART.

Number of included participants: Participants will be matched 1:1 with 35,000 women in each arm.

Intervention: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.

Study Duration: There will be two database locks in SMART. The primary lock is done after approximately four years and two months. Women participating in SMART are part of the initial recruitment phase for a total of two years. They perform mammograms at baseline and 24 months. Adding the 2 year follow up for the lastly recruited participant makes a full trial period 4 years in total, with a further two months allowed to capture women whose scan is delayed. After two months the investigators will consider that screening visit to have been missed. The number of high-risk women will be slightly more than 6,000 in each arm (see 10.1 Population / Power). In addition, a second data lock will be performed after 8 years and two months from the start of the trial, that is, after a fourth round of screens (baseline plus 3 routine follow up mammograms). The same objectives and endpoints will be addressed as after the first data base lock with the exception of questionnaire data. Questionnaire data will only be collected between baseline and the next screen in 24 months. SMART will start in 2024, recruit women for 2 years and follow all women for 6 years. The study will thus end in 2032.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have read, understood and signed the
  • Perform breast cancer screening at Södersjukhuset
  • Females in the age range 40 - 74 years at baseline mammography
  • Using a smartphone or tablet with BankID

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breast feeding or planning to become pregnant.
  • Previous breast cancer
  • A medical condition that according to the responsible physician would negatively affect the health of the women.
  • Cognitive impairment and / or language ability that would make it difficult for the participant to understand the implication of study and to perform a contrast mammography.

For women that will be offered contrast enhanced mammography the clinically accepted and applied exclusion criteria will be used. Women who cannot perform a contrast mammography will be offered an automated ultrasound.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70,000 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Women randomised to the experimental arm / individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an AI (artificial intelligence) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months.

    Procedure: Risk based screening

  • Active comparator
    No intervention arm

    The 35,000 women randomised to the no intervention arm will continue in the Swedish National Breast Cancer Screening Program. This means that they are invited for the next mammography screening after 24 months.

    Procedure: Risk based screening

Interventions

  • ProcedureRisk based screening

    Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.

06

What researchers measure

Primary outcomes

  1. Incidence of interval cancers

    For women at high 2-year risk in the intervention arm interval cancers are defined as cancers diagnosed in the interval between CEM and 12-month mammogram plus in the interval between 12- and 24-month interval. For the remaining women in the trial interval cancers are defined as cancers diagnosed between baseline mammography and 24-month mammography.

    Time frame: 24-month

Secondary outcomes

  1. Number of recalled women

    Information on number of women recalled from screening mammography.

    Time frame: 24-month

Other outcomes

  1. Number of biopsies

    Information on number of biopsies in recalled women.

    Time frame: 24-month

  2. Breast cancer

    Y/N , if yes:date of diagonosis.

    Time frame: 24-month

  3. Tumor characteristics - Stage

    Breast cancer stage 0-4

    Time frame: 24-month

  4. Tumor characteristics - Multifocality

    Unifocal or multifocal

    Time frame: 24-month

  5. Tumor characteristics - Receptor status

    Hormone Receptor Status, to assess the presence of estrogen receptors (ER) and progesterone receptors (PR). HER2 Status, is used to determine whether the cancer cells overexpress the HER2 protein.

    Time frame: 24-month

  6. Tumor characteristics - Proliferation

    Ki-67 Index, provides information about the tumor's proliferative activity.

    Time frame: 24-month

  7. Cancer worry

    Measurement of cancer worry will be done by using answers from the self-reported Cancer Worry Scale (8-item CWS). 8-item CWS measure cancer worry, score with Likert scale response, four options from min to max cancer worry.

    Time frame: 24-month

  8. Cancer anxiety

    Measurement of cancer anxiety will be done by using answers from the self-reported State Trait Anxiety Inventory (STAI-6). STAI-6 measure anxiety. Questions rated on a 4-point Likert scale, options scores from "Not at all" to "Very much" anxiety.

    Time frame: 24-month

  9. Side effects related to contrast enhanced mammography

    The possible side effects related to contrast enhanced mammography and ordinary mammography will be identified using the self-reported Test Morbidity Index.

    Time frame: 24-month

  10. Cost-effectiveness

    Cost-effectiveness will be presented in incremental cost-effectiveness ratio (ICER).

    Time frame: 24-month

  11. Willingness-to-pay

    Willingness-to-pay is defined as the maximum amount that society is willing to pay for each quality adjusted life year (QALY). One quality-adjusted life year (QALY) is equal to 1 year of life in perfect health. Scores range from 1 (perfect health) to 0 (dead).

    Time frame: 24-month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Apr 2028, 48 months later.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 48 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Feb 21, 2024
StartEst.
Apr 8, 2024
Primary completionEst.
Apr 8, 2028
CompletionEst.
Apr 8, 2032
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06270355
Responsible party
Per Hall (Professor, PhD, MD, Karolinska Institutet) — Principal investigator
First posted
Feb 21, 2024
Start date
Apr 8, 2024 (estimated)
Primary completion
Apr 8, 2028 (estimated)
Completion
Apr 8, 2032 (estimated)
Last update
Feb 28, 2024

Study contacts

Per Hall, Professor
Contact
per.hall@ki.se
+46 8-524 823 39
Mattias Hammarström, CTM
Contact
mattias.hammarstrom@ki.se
+46 737121476
Per Hall, Professor
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion